MNOV
$1.47
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory ...
Recent News
MediciNova: Q4 Earnings Snapshot
LA JOLLA, Calif. AP) — MediciNova Inc. MNOV) on Friday reported a loss of $2.8 million in its fourth quarter.
ATA Creativity Global Among 3 Promising Penny Stocks
As the U.S. stock market faces a challenging period with major indexes posting weekly losses and Treasury yields reaching a four-month high, investors are keenly observing potential opportunities in various sectors. Penny stocks, often associated with smaller or newer companies, remain an intriguing area for those seeking growth prospects outside of the mainstream market giants. Despite being considered somewhat niche today, penny stocks can still offer significant potential when backed by...
MediciNova: Q3 Earnings Snapshot
LA JOLLA, Calif. AP) — MediciNova Inc. MNOV) on Wednesday reported a loss of $3.1 million in its third quarter.
3 Penny Stocks With Market Caps Over $80M To Consider
As the United States stock market continues to post gains, boosted by strong performances from tech giants like Amazon, investors are exploring diverse opportunities across various sectors. Penny stocks, while often considered a relic of past trading days, still hold relevance as they offer potential growth at lower price points. When backed by solid financials and robust fundamentals, these smaller or newer companies can defy expectations and present significant returns.
MediciNova compounds demonstrate novel therapeutic approach for Atherosclerosis
MediciNova (MNOV) and the Standard Market of the Tokyo Stock Exchange announces the publication of a new research article in the peer-reviewed Journal of Atherosclerosis and Thrombosis, the official journal of the Japan Atherosclerosis Society and the Asian Pacific Society of Atherosclerosis and Vascular Disease. The study, titled, “Enhancement of ABCA1 and ABCG1 Expression and Cholesterol Efflux by a Metabolite of Tipelukast: A Potential Therapeutic Strategy for Atherosclerosis,” is the result